Teva in $7.4 billion Barr buy

Share this article:
Teva is buying Montvale, NJ-based Barr Pharmaceuticals for $7.4 billion and will take on debt of $1.5 billion.

The move gives the Jerusalem-based generics giant a host of generic drugs, branded contraceptives, including Seasonique and Plan B, and access to Eastern European markets. It comes at a time when generics' share of the US market is surging. With the acquisition, Teva will have a quarter of the US market, said president and CEO Shlomo Yanai in an interview with Bloomberg.
 
Together, the companies employ around 37,000 in 60 countries and had nearly $12 billion in revenues in 2007.
 
Last year, generics accounted for 67% of total US dispensed prescriptions according to IMS Health.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.